Equities Analysts Offer Predictions for GPCR Q2 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Analysts at Lifesci Capital raised their Q2 2026 earnings estimates for Structure Therapeutics in a note issued to investors on Friday, May 8th. Lifesci Capital analyst P. Dolezal now forecasts that the company will earn ($0.43) per share for the quarter, up from their prior forecast of ($0.48). The consensus estimate for Structure Therapeutics’ current full-year earnings is ($1.36) per share. Lifesci Capital also issued estimates for Structure Therapeutics’ Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.70) EPS, Q4 2027 earnings at ($0.55) EPS and FY2027 earnings at ($2.05) EPS.

Several other research firms have also commented on GPCR. Wolfe Research assumed coverage on shares of Structure Therapeutics in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen upgraded shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, The Goldman Sachs Group upgraded shares of Structure Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 20th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $109.25.

Structure Therapeutics Stock Down 2.0%

Shares of Structure Therapeutics stock opened at $38.32 on Tuesday. The company has a market cap of $2.71 billion, a P/E ratio of -44.05 and a beta of -1.31. The firm’s 50 day moving average price is $50.79 and its 200-day moving average price is $56.28. Structure Therapeutics has a 52-week low of $15.80 and a 52-week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP raised its position in shares of Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after purchasing an additional 1,432,797 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Structure Therapeutics by 21.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after buying an additional 1,150,000 shares during the last quarter. Janus Henderson Group PLC raised its position in Structure Therapeutics by 14.4% during the 4th quarter. Janus Henderson Group PLC now owns 5,090,148 shares of the company’s stock worth $354,006,000 after buying an additional 641,322 shares during the last quarter. BVF Inc. IL raised its position in Structure Therapeutics by 8.6% during the 4th quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock worth $241,966,000 after buying an additional 275,105 shares during the last quarter. Finally, Morgan Stanley grew its stake in shares of Structure Therapeutics by 261.4% during the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after purchasing an additional 1,510,093 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.